Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Hepatitis C

Treatments: Other: Non-interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03366610

AI444-412

Details and patient eligibility

About

The purpose of this study is to assess long-term outcomes in subjects previously treated with daclatasvir-based therapy for chronic Hepatitis-C (CHC)

Enrollment: 199 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females 18 years of age or older at initiation of prior DCV-based therapy
• Previously treated with DCV (manufactured by BMS)-based therapy in combination with other HCV direct acting antivirals (DAAs) for at least 8 weeks
• Must enroll in this study within 12 months of end of treatment of DCV-based therapy or within 6 months of protocol availability at the clinical site for subjects treated in the AI447036 or AI447114 studies

Exclusion criteria

• N/A

Trial design

199 participants in 1 patient group

Patients Previously Treated with Daclatasvir-Based Regimens

Description:

Patients in China Previously Treated with Daclatasvir-Based Regimens

Treatment:

Other: Non-interventional